Clinical Trial Update: Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on PLX-200 for Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) describing safety, tolerability, and efficacy; the study is not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Neuronal Ceroid Lipofuscinosis

Drugs mentioned

• PLX-200 (PLX-200)

Snippet

Sponsor: Polaryx Therapeutics, Inc. | Conditions: Juvenile Neuronal Ceroid Lipofuscinosis | Phase 3 | Status: NOT_YET_RECRUITING